Zydus receives final approval from US FDA for Lacosamide Injection

Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) to market Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL) single-dose vials, a company statement notified.

Lacosamide Injection is used to treat partial-onset seizures. It is also used with other medicines to treat primary generalised tonic-clonic seizures. It acts on the Central Nervous System (CNS) to reduce the number and severity of seizures, the statement added.

It also said that the drug will be manufactured at the group’s injectables manufacturing facility at Jarod, India.